Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi
NCT ID: NCT00177086
Last Updated: 2013-03-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
76 participants
INTERVENTIONAL
2005-09-30
2008-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ALF-STONE: Alfuzosin in Uretheric Stones
NCT00454402
Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy
NCT00409227
Alfuzosin for Medical Expulsion Therapy of Ureteral Stones
NCT00713739
The Use of Medical-Expulsive Therapy With Alfuzocine xl 10mg x1/d for Distal Ureterolithiasis.a Randomized Prospective Study
NCT00489112
Use of Alfuzosin in Stone Treatment With ESWL
NCT00388271
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Alfuzosin
Alfuzosin Hydrochloride
One tablet every day for 4 weeks
Placebo
Alfuzosin Hydrochloride
One tablet every day for 4 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alfuzosin Hydrochloride
One tablet every day for 4 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \<8mm ureteral calculus below the pelvic brim identified by non-contrast CT scan and/or intravenous pyelogram
Exclusion Criteria
* Pregnant/Nursing females
* Solitary kidney
* Renal insufficiency (Creatinine\>1.8)
* Urinary infection (fever \>101, positive urine culture, many bacteria on urinalysis)
* Moderate or severe hepatic insufficiency (Childs-Pugh categories B and C)
* Potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since Alfuzosin blood levels are increased
* Other alpha-blockers
* Phosphodiesterase type 5 inhibitors for erectile dysfunction
* Any subject for whom the principal investigator feels it would not be in his or her best interest to participate in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Manoj, Monga, M.D.
INDIV
University of Minnesota
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Manoj Monga, MD
Role: PRINCIPAL_INVESTIGATOR
University of Minnesota and VAMC Minneapolis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Minnesota
Minneapolis, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
L9839
Identifier Type: -
Identifier Source: secondary_id
3579B
Identifier Type: -
Identifier Source: secondary_id
0412M65851
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.